Johnson & Johnson and AbbVie both beat Q1 2026 revenue expectations but pursue contrasting strategies, with the better choice depending on investor type.
Finnhub07/10, 10:30 PM
Related assets
Coming up for JNJ
Explore next
Latest JNJ news
Finnhub08/27, 12:50 PM
Johnson & Johnson's autoimmune drug received FDA approval for treatment of a rare blood disease.
FirstSquawk08/08, 08:14 AM
Duato sold 41,957 J&J shares at an average price of $258.06.
FirstSquawk08/08, 08:13 AM
J&J's Duato disclosed a share sale of $1.69M at an average price of $258.74.